The productivity and efficiency of continuous manufacturing have long been exploited for benefit in bulk chemical production applications. For decades chemical manufacturers have put continuous manufacturing processes to good use, producing millions of metric tonnes annually utilising a relatively small manufacturing footprint. Often tens of per cent of the global production of large volume products are processed through only one or a few facilities. In years past, drug manufacturing has been done exclusively via batch processing methods. In fact, until recently, no commercialised drugs were produced with continuous manufacturing methods. Over the past fifteen years, some pharmaceutical groups have begun to explore the potential for employing continuous manufacturing methods in drug manufacturing. And in the past three years, those efforts have begun to accelerate with the deployment of continuous manufacturing methods across the pharmaceutical industry increasing rapidly. The majority of the top 20 large pharmaceutical companies now have programmes ongoing in the area ranging from early-stage exploratory research to full-scale transformation of commercial processes. Eli Lilly and Company, for example, has recently made a US$40 million investment to build a continuous manufacturing facility at its Kinsale, Ireland manufacturing plant.